Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4274/tjh.galenos.2025.2025.0166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Respiratory Distress Syndrome Phenotypes After Stem Cell Transplantation: A Latent Class Analysis.
Crit Care Explor
September 2025
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Objective: To identify distinct phenotypes of acute respiratory distress syndrome (ARDS) developing after hematopoietic cell transplantation (HCT), using routinely available clinical data at ICU admission.
Design: Multicenter retrospective cohort study using latent class analysis.
Setting: ICUs across three Mayo Clinic campuses (Minnesota, Florida, and Arizona).
Noninfectious pulmonary complications after hematopoietic cell transplantation: a comprehensive review.
Respir Med
September 2025
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hematopoietic stem cell transplant (HSCT) is a cornerstone for the treatment of high-risk hematologic malignancies. The efficacy of HSCT is limited by transplant-related complications, particularly pulmonary complications. Broadly speaking, the myriads of non-infectious complications that occur after HSCT are less completely understood than infectious complications despite contributing to significant morbidity and mortality.
View Article and Find Full Text PDFRuxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Front Immunol
September 2025
School of Medicine, Nankai University, Tianjin, China.
Purpose: Relapse remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome-IB (MDS-IB) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib has demonstrated antileukemic activity , and decitabine has been found to be tolerable when combined with modified busulfan-cyclophosphamide (mBu/Cy) conditioning regimen. Here, we investigated the efficacy of ruxolitinib and decitabine plus a mBu/Cy conditioning regimen (Rux-Dec-mBu/Cy) in reducing relapse in high-risk AML/MDS patients ().
View Article and Find Full Text PDFOnce-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children.
Pharmaceutics
August 2025
Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.Box 12272, Jerusalem 9112102, Israel.
Busulfan is a key component of myeloablative conditioning regimens in hematopoietic stem cell transplantation (HSCT) for pediatric patients with acute myeloid leukemia, solid tumors, and certain non-malignant diseases. This study compares the clinical outcomes of once-daily (BU1) versus four-times-daily (BU4) busulfan dosing regimens in pediatric HSCT recipients. A retrospective analysis was conducted on 70 pediatric patients who underwent HSCT at Hadassah Medical Center between June 2018 and October 2023.
View Article and Find Full Text PDFPost-engraftment syndrome (PES) is a significant and potentially life-threatening complication of autologous haematopoietic stem cell transplantation (AHSCT) that presents with fever, skin rash and pulmonary involvement. Despite its clinical relevance, PES remains a diagnostic challenge and is often misidentified as an infectious process, leading to a delay in the appropriate treatment. We report the case of a 38-year-old man with relapsed Hodgkin's lymphoma and glucose-6-phosphate dehydrogenase (G6PD) deficiency who developed severe PES following AHSCT.
View Article and Find Full Text PDF